Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV100 + Polymyxin B in CRAB VABP
NCT05685615Phase 2Completed
- Sponsor
- BioVersys AG
- Start
- Apr 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of BV100 in ventilator-associated pneumonia (VAP) (4 arms), sponsored by BioVersys AG. Primary endpoint: Pharmacokinetic properties of BV100 co-administered with Polymyxin B at 14 days. Started Apr 2023; status: completed.
02
Drugs
BV100
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT05685615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685615.